triple glp 1 Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor agonist GLP-1-based therapies for type 2

Synthesis and characterization

Utilizing electrostatic interactions, positively charged COFs were successfully loaded with Poly(I:C), followed by coating MnO 2 on the surface via an in-situ growth strategy, ultimately yielding MnO 2 -Poly(I:C)@COF composites ( Figure 4D )

Mounjaro also acts on a second hormone pathway, and early trials suggest it may produce even greater weight loss than semaglutide alone

CagriSema Weight Loss Results at a Glance Adults without diabetes: 20.4% average, 22.7% with adherence Adults with type 2 diabetes: 13.7% average, 15.7% with adherence Placebo: 3% (non-diabetic) and 3.4% (diabetic) 40.4% of REDEFINE 1 participants reached 25%+ weight loss CagriSema Dosing and Dosage Chart CagriSema Side Effects Nausea Vomiting Diarrhea Constipation Loss of appetite CagriSema vs Tirzepatide, Zepbound, Semaglutide and Retatrutide CagriSema vs Tirzepatide (and Zepbound) Tirzepatide is a single molecule that hits both GLP-1 and GIP receptors, and it is sold as Zepbound for weight loss and Mounjaro for diabetes